{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:23:29Z","timestamp":1775208209540,"version":"3.50.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11906-020-01092-8","type":"journal-article","created":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T12:02:31Z","timestamp":1599307351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy"],"prefix":"10.1007","volume":"22","author":[{"given":"Maximillian T.","family":"Bourdillon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramachandran S.","family":"Vasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,5]]},"reference":[{"key":"1092_CR1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey R, Aronow WS, Casey D, Collins K, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Pr. J Am Coll Cardiol. 2018;71:127\u2013248.","journal-title":"J Am Coll Cardiol"},{"key":"1092_CR2","first-page":"e139","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association. Circulation. 2020;141:e139\u2013596.","journal-title":"Circulation."},{"key":"1092_CR3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/jhh.2011.104","volume":"26","author":"C Cuspidi","year":"2012","unstructured":"Cuspidi C, Sala C, Negri F, Mancia G, Morganti A. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens Nature Publishing Group. 2012;26:343\u20139.","journal-title":"J Hum Hypertens"},{"key":"1092_CR4","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ajh\/hpx067","volume":"30","author":"CN Bang","year":"2017","unstructured":"Bang CN, Soliman EZ, Simpson LM, Davis BR, Devereux RB, Okin PM. Electrocardiographic left ventricular hypertrophy predicts cardiovascular morbidity and mortality in hypertensive patients: the ALLHAT study. Am J Hypertens. Oxford Academic. 2017;30:914\u201322.","journal-title":"Am J Hypertens"},{"key":"1092_CR5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jelectrocard.2014.06.002","volume":"47","author":"PM Rautaharju","year":"2014","unstructured":"Rautaharju PM, Soliman EZ. Electrocardiographic left ventricular hypertrophy and the risk of adverse cardiovascular events: a critical appraisal. J Electrocardiol. 2014;47:649\u201354.","journal-title":"J Electrocardiol"},{"key":"1092_CR6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/HJH.0000000000000882","volume":"34","author":"AO Lehtonen","year":"2016","unstructured":"Lehtonen AO, Puukka P, Varis J, Porthan K, Tikkanen JT, Nieminen MS, et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens. 2016;34:959\u201366.","journal-title":"J Hypertens"},{"key":"1092_CR7","doi-asserted-by":"crossref","unstructured":"Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JAC. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging; Elsevier. 2012;5(8):837\u201348.","DOI":"10.1016\/j.jcmg.2012.06.003"},{"key":"1092_CR8","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.jacc.2008.09.014","volume":"52","author":"DA Bluemke","year":"2008","unstructured":"Bluemke DA, Kronmal RA, Lima JAC, Liu K, Olson J, Burke GL, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (multi-ethnic study of atherosclerosis) study. J Am Coll Cardiol Elsevier. 2008;52:2148\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"1092_CR9","doi-asserted-by":"crossref","unstructured":"Bouzas-Mosquera A, Broull\u00f3n FJ, \u00c1lvarez-Garc\u00eda N, Peteiro J, Mosquera VX, Castro-Beiras A. Association of left ventricular mass with all-cause mortality, myocardial infarction and stroke. PLoS One. 2012;7(9):e45570.","DOI":"10.1371\/journal.pone.0045570"},{"key":"1092_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/HYPERTENSIONAHA.109.141887","volume":"55","author":"J D\u00edez","year":"2010","unstructured":"D\u00edez J, Frohlich EDA. Translational approach to hypertensive heart disease. Hypertension. 2010;55:1\u20138.","journal-title":"Hypertension."},{"key":"1092_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11906-020-1017-9","volume":"22","author":"CC Nwabuo","year":"2020","unstructured":"Nwabuo CC, Vasan RS. Pathophysiology of hypertensive heart disease: beyond left ventricular hypertrophy. Curr Hypertens Rep Springer. 2020;22:11.","journal-title":"Curr Hypertens Rep"},{"key":"1092_CR12","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for themanagement of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"1092_CR13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jama.1996.03530430051039","volume":"275","author":"RE Schmieder","year":"1996","unstructured":"Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. JAMA. 1996;275:1507\u201313.","journal-title":"JAMA."},{"key":"1092_CR14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","volume":"115","author":"AU Klingbeil","year":"2003","unstructured":"Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41\u20136.","journal-title":"Am J Med"},{"key":"1092_CR15","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","volume":"54","author":"RH Fagard","year":"2009","unstructured":"Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084\u201391.","journal-title":"Hypertension."},{"key":"1092_CR16","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/hc3901.096700","volume":"104","author":"J Mathew","year":"2001","unstructured":"Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615\u201321.","journal-title":"Circulation."},{"key":"1092_CR17","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/01.CIR.0000083724.28630.C3","volume":"108","author":"PM Okin","year":"2003","unstructured":"Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. Circulation. 2003;108:684\u201390.","journal-title":"Circulation."},{"key":"1092_CR18","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","volume":"110","author":"RB Devereux","year":"2004","unstructured":"Devereux RB, Dahl\u00f6f B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456\u201362.","journal-title":"Circulation."},{"key":"1092_CR19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ajh\/hpx171","volume":"31","author":"C Bertoluci","year":"2018","unstructured":"Bertoluci C, Foppa M, Santos ABS, Branchi TV, Fuchs SC, Fuchs FD. Echocardiographic left ventricular reverse remodeling after 18 months of antihypertensive treatment in stage I hypertension. Results from the Prever-Treatment study. Am J Hypertens. Oxford Academic. 2018;31:321\u20138.","journal-title":"Am J Hypertens"},{"key":"1092_CR20","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334\u201357.","journal-title":"Hypertension."},{"key":"1092_CR21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(09)61340-4","volume":"374","author":"P Verdecchia","year":"2009","unstructured":"Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (cardio-sis): an open-label randomised trial. Lancet. 2009;374:525\u201333.","journal-title":"Lancet."},{"key":"1092_CR22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/HYPERTENSIONAHA.115.06236","volume":"66","author":"EZ Soliman","year":"2015","unstructured":"\u2022 Soliman EZ, Byington RP, Bigger JT, Evans G, Okin PM, Goff DC, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: action to control cardiovascular risk in Diabetes Blood Pressure Trial. Hypertens (Dallas, Tex 1979). 2015;66:1123\u20139 This study highlighted the benefit of intensive SBP lowering (<\u2009120 mm Hg) on ECG-LVH regression compared with standard care (goal SBP <\u2009140 mm Hg) in patients with diabetes mellitus.","journal-title":"Hypertens (Dallas, Tex 1979)"},{"key":"1092_CR23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/CIRCULATIONAHA.117.028441","volume":"136","author":"EZ Soliman","year":"2017","unstructured":"\u2022\u2022 Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension. Circulation. 2017;136:440\u201350 This study underscored the benefit of intensive SBP lowering (<\u2009120 mmHg) on regression of ECG-LVH compared with standard care (goal SBP <\u2009140\u00a0mmHg) in patients without diabetes mellitus.","journal-title":"Circulation"},{"key":"1092_CR24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/jhh.2013.20","volume":"27","author":"K Zhang","year":"2013","unstructured":"Zhang K, Chen J, Liu Y, Wang T, Wang L, Wang J, et al. Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2013;27:698\u2013706.","journal-title":"J Hum Hypertens"},{"key":"1092_CR25","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jch.13386","volume":"20","author":"GC Roush","year":"2018","unstructured":"\u2022\u2022 Roush GC, Abdelfattah R, Song S, Ernst ME, Sica DA, Kostis JB. Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing\/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: a systematic review and meta-analysis. J Clin Hypertens. 2018;20:1507\u201315 This contemporary meta-analysis underscores the differences in efficacy on LVM regression between different thiazide-type diuretic regimens. CHIP diuretics, and in particular chlorthalidone and indapamide, demonstrated superior efficacy for reducing LVM compared with HCTZ.","journal-title":"J Clin Hypertens"},{"key":"1092_CR26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.phrs.2018.06.026","volume":"134","author":"M Salvetti","year":"2018","unstructured":"\u2022\u2022 Salvetti M, Paini A, Bertacchini F, Stassaldi D, Aggiusti C, Agabiti Rosei C, et al. Changes in left ventricular geometry during antihypertensive treatment. Pharmacol Res. 2018;134:193\u20139 This contemporary meta-analysis highlights the inferiority of \u03b2-blockers on regression of echocardiographic LVM compared with CCBs, ACEi, ARBs, and diuretics.","journal-title":"Pharmacol Res"},{"key":"1092_CR27","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"1092_CR28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/HYPERTENSIONAHA.114.04581","volume":"65","author":"SS Franklin","year":"2015","unstructured":"Franklin SS, Gokhale SS, Chow VH, Larson MG, Levy D, Vasan RS, et al. Does low diastolic blood pressure contribute to the risk of recurrent hypertensive cardiovascular disease events?: the Framingham Heart Study. Hypertension. 2015;65:299\u2013305.","journal-title":"Hypertension."},{"key":"1092_CR29","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehq328","volume":"31","author":"S Bangalore","year":"2010","unstructured":"Bangalore S, Messerli FH, Wun C-C, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating To New Targets (TNT) trial. Eur Heart J. 2010;31:2897\u2013908.","journal-title":"Eur Heart J"},{"key":"1092_CR30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/HYPERTENSIONAHA.119.12787","volume":"74","author":"S Lip","year":"2019","unstructured":"Lip S, Tan LE, Jeemon P, McCallum L, Dominiczak AF, Padmanabhan S. Diastolic blood pressure J-curve phenomenon in a tertiary-care hypertension clinic. Hypertension. 2019;74:767\u201375.","journal-title":"Hypertension."},{"key":"1092_CR31","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.117.030342","volume":"136","author":"DN Kalkman","year":"2017","unstructured":"Kalkman DN, Brouwer TF, Vehmeijer JT, Berger WR, Knops RE, de Winter RJ, et al. J curve in patients randomly assigned to different systolic blood pressure targets: an experimental approach to an observational paradigm. Circulation. 2017;136:2220\u20139.","journal-title":"Circulation."},{"key":"1092_CR32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/HYPERTENSIONAHA.119.13073","volume":"74","author":"B Upadhya","year":"2019","unstructured":"Upadhya B, Rocco MV, Pajewski NM, Morgan T, Blackshear J, Hundley WG, et al. Effect of intensive blood pressure reduction on left ventricular mass, structure, function, and fibrosis in the SPRINT-HEART. Hypertension. 2019;74:276\u201384.","journal-title":"Hypertension."},{"key":"1092_CR33","doi-asserted-by":"crossref","unstructured":"Simpson HJ, Gandy SJ, Houston JG, Rajendra NS, Davies JI, Struthers AD, et al. Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular mass Hypertension. Heart. 2010 [cited 2020 Aug 2];96:148\u201352. Available from: http:\/\/heart.bmj.com\/","DOI":"10.1136\/hrt.2009.177238"},{"key":"1092_CR34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjcard.2014.11.037","volume":"115","author":"L Bacharova","year":"2015","unstructured":"Bacharova L, Chen H, Estes EH, Mateasik A, Bluemke DA, Lima JAC, et al. Determinants of discrepancies in detection and comparison of the prognostic significance of left ventricular hypertrophy by electrocardiogram and cardiac magnetic resonance imaging. Am J Cardiol. 2015;115:515.","journal-title":"Am J Cardiol"},{"key":"1092_CR35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ajh\/5.2.95","volume":"5","author":"B Dahl\u00f6f","year":"1992","unstructured":"Dahl\u00f6f B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients a metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5:95\u2013110.","journal-title":"Am J Hypertens"},{"key":"1092_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.116.004152","volume":"6","author":"MT L\u00f8nnebakken","year":"2017","unstructured":"L\u00f8nnebakken MT, Izzo R, Mancusi C, Gerdts E, Losi MA, Canciello G, et al. Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania salute network). J Am Heart Assoc. 2017;6:1\u20138.","journal-title":"J Am Heart Assoc"},{"key":"1092_CR37","doi-asserted-by":"crossref","unstructured":"Pucci G, Ranalli MG, Battista F, Schillaci G. Effects of \u03b2-blockers with and without vasodilating properties on central blood pressure. Hypertension. Lippincott Williams & Wilkins Hagerstown, MD; 2016;67:316\u201324.","DOI":"10.1161\/HYPERTENSIONAHA.115.06467"},{"key":"1092_CR38","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/HYPERTENSIONAHA.110.155507","volume":"57","author":"P Kampus","year":"2011","unstructured":"Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:1122\u20138.","journal-title":"Hypertension."},{"key":"1092_CR39","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/jch.12210","volume":"15","author":"P Studinger","year":"2013","unstructured":"Studinger P, Tab\u00e1k \u00c1G, Chen C-H, Salvi P, Othmane TEH, Torzsa P, et al. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. J Clin Hypertens. 2013;15:910\u20137.","journal-title":"J Clin Hypertens"},{"key":"1092_CR40","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/HJH.0b013e328364fbca","volume":"31","author":"DW Eeftinck Schattenkerk","year":"2013","unstructured":"Eeftinck Schattenkerk DW, Van Den Bogaard B, Cammenga M, Westerhof BE, Stroes ESG, Van Den Born BJH. Lack of difference between nebivolol\/hydrochlorothiazide and metoprolol\/hydrochlorothiazide on aortic wave augmentation and central blood pressure. J Hypertens. 2013;31:2447\u201354.","journal-title":"J Hypertens"},{"key":"1092_CR41","doi-asserted-by":"crossref","unstructured":"\u2022 Xing FW, Chen J, Zhao BL, Jiang J, Tang A, Chen Y. Real role of \u03b2-blockers in regression of left ventricular mass in hypertension patients. Med (United States). 2017;96(10):e6290. This current meta-analysis suggests that \u03b2-blockers may not be uniformly inferior to other classes of antihypertensives with respect to LVH regression by demonstrating a similar efficacy on reducing LVH between fat-soluble \u03b2-blockers, ACEi, and ARBs.","DOI":"10.1097\/MD.0000000000006290"},{"key":"1092_CR42","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/01.CIR.91.3.698","volume":"91","author":"PR Liebson","year":"1995","unstructured":"Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH, Neaton JD, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation. 1995;91:698\u2013706.","journal-title":"Circulation."},{"key":"1092_CR43","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jash.2016.10.010","volume":"10","author":"ME Ernst","year":"2016","unstructured":"Ernst ME, Davis BR, Soliman EZ, Prineas RJ, Okin PM, Ghosh A, et al. Electrocardiographic measures of left ventricular hypertrophy in the antihypertensive and lipid-lowering to prevent heart attack trial. J Am Soc Hypertens. 2016;10:930\u20138.","journal-title":"J Am Soc Hypertens"},{"key":"1092_CR44","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/HYPERTENSIONAHA.111.181248","volume":"58","author":"ME Ernst","year":"2011","unstructured":"Ernst ME, Neaton JD, Grimm RH, Collins G, Thomas W, Soliman EZ, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension. 2011;58:1001\u20137.","journal-title":"Hypertension."},{"key":"1092_CR45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ajh.2010.1","volume":"23","author":"ME Ernst","year":"2010","unstructured":"Ernst ME, Carter BL, Zheng S, Grimm RH. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440\u20136.","journal-title":"Am J Hypertens"},{"key":"1092_CR46","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/HYPERTENSIONAHA.110.168054","volume":"58","author":"CJ Rodriguez","year":"2011","unstructured":"Rodriguez CJ, Bibbins-Domingo K, Jin Z, Daviglus ML, Goff DC, Jacobs DR. Association of sodium and potassium intake with left ventricular mass. Hypertension. 2011;58:410\u20136.","journal-title":"Hypertension."},{"key":"1092_CR47","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/HJH.0000000000001691","volume":"36","author":"GC Roush","year":"2018","unstructured":"\u2022\u2022 Roush GC, Abdelfattah R, Song S, Kostis JB, Ernst ME, Sica DA. Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. J Hypertens. 2018;36:1247\u201355 This meta-analysis demonstrated greater reductions in LVM by TTE with CHIP diuretics compared with ACEi and ARBs.","journal-title":"J Hypertens"},{"key":"1092_CR48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","volume":"57","author":"J V\u00e1clav\u00edk","year":"2011","unstructured":"V\u00e1clav\u00edk J, Sedl\u00e1k R, Plach\u00fd M, Navr\u00e1til K, Pl\u00e1\u0161ek J, Jarkovsk\u00fd J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069\u201375.","journal-title":"Hypertension."},{"key":"1092_CR49","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet."},{"key":"1092_CR50","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jcmg.2017.04.001","volume":"10","author":"W Kosmala","year":"2017","unstructured":"Kosmala W, Sanders P, Marwick TH. Subclinical myocardial impairment in metabolic diseases. JACC Cardiovasc Imaging. 2017;10:692\u2013703.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1092_CR51","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy. Circulation. 2003;108:1831\u20138.","journal-title":"Circulation."},{"key":"1092_CR52","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/HJH.0000000000001264","volume":"35","author":"A Schneider","year":"2017","unstructured":"Schneider A, Schwab J, Karg MV, Kalizki T, Reinold A, Schneider MP, et al. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension. J Hypertens. 2017;35:1086\u201392.","journal-title":"J Hypertens"},{"key":"1092_CR53","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehv142","volume":"36","author":"C Bavishi","year":"2015","unstructured":"Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J. 2015;36:1967\u201373.","journal-title":"Eur Heart J"},{"key":"1092_CR54","doi-asserted-by":"crossref","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010:1255\u201366.","DOI":"10.1016\/S0140-6736(09)61966-8"},{"key":"1092_CR55","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"1092_CR56","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","volume":"63","author":"K Kario","year":"2014","unstructured":"Kario K, Sun N, Chiang F-T, Supasyndh O, Baek SH, Inubushi-Molessa A, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension. Hypertension. 2014;63:698\u2013705.","journal-title":"Hypertension."},{"key":"1092_CR57","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","volume":"38","author":"RE Schmieder","year":"2017","unstructured":"\u2022 Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, et al. The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38:3308\u201317 This is the first randomized controlled trial to highlight the efficacy of angiotensin II receptor blocker neprilysin inhibitors (ARNI) on LVH regression measured by cMRI.","journal-title":"Eur Heart J"},{"key":"1092_CR58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","volume":"69","author":"B Williams","year":"2017","unstructured":"\u2022 Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al. Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension. Hypertension. 2017;69:411\u201320 This randomized trial provides mechanistic insight that may underscore the utility of angiotensin II receptor neprilysin inhibitors (ARNI) on LVH regression through attenuation of central aortic pulse pressures.","journal-title":"Hypertension"},{"key":"1092_CR59","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","volume":"322","author":"AS Desai","year":"2019","unstructured":"Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction. JAMA. 2019;322:1077.","journal-title":"JAMA."},{"key":"1092_CR60","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1092_CR61","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140:1693\u2013702.","journal-title":"Circulation."},{"key":"1092_CR62","doi-asserted-by":"crossref","unstructured":"Lan NSR, Fegan PG, Yeap BB, Dwivedi G. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Hear Fail. 2019;6(5):927\u201335.","DOI":"10.1002\/ehf2.12505"},{"key":"1092_CR63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","volume":"344","author":"FM Sacks","year":"2001","unstructured":"Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med. 2001;344:3\u201310.","journal-title":"N Engl J Med"},{"key":"1092_CR64","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.amjcard.2015.02.008","volume":"115","author":"B Haring","year":"2015","unstructured":"Haring B, Wang W, Lee ET, Jhamnani S, Howard BV, Devereux RB. Effect of dietary sodium and potassium intake on left ventricular diastolic function and mass in adults \u226440 years (from the strong heart study). Am J Cardiol Elsevier. 2015;115:1244\u20138.","journal-title":"Am J Cardiol Elsevier"},{"key":"1092_CR65","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1161\/01.CIR.89.3.1023","volume":"89","author":"AM Jula","year":"1994","unstructured":"Jula AM, Karanko HM. Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. Circulation. 1994;89:1023\u201331.","journal-title":"Circulation."},{"key":"1092_CR66","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/ajh.2009.45","volume":"22","author":"A Vaidya","year":"2009","unstructured":"Vaidya A, Bentley-Lewis R, Jeunemaitre X, Adler GK, Williams JS. Dietary sodium alters the prevalence of electrocardiogram determined left ventricular hypertrophy in hypertension. Am J Hypertens. 2009;22:669\u201373.","journal-title":"Am J Hypertens"},{"key":"1092_CR67","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/bmj.39147.604896.55","volume":"334","author":"NR Cook","year":"2007","unstructured":"Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). Br Med J. 2007;334:885\u20138.","journal-title":"Br Med J"},{"key":"1092_CR68","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/archinternmed.2009.470","volume":"170","author":"JA Blumenthal","year":"2010","unstructured":"Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170:126\u201335.","journal-title":"Arch Intern Med"},{"key":"1092_CR69","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.amjcard.2014.11.038","volume":"115","author":"H Gardener","year":"2015","unstructured":"Gardener H, Rundek T, Wright CB, Gu Y, Scarmeas N, Homma S, et al. A Mediterranean-style diet and left ventricular mass (from the Northern Manhattan study). Am J Cardiol. 2015;115:510.","journal-title":"Am J Cardiol"},{"key":"1092_CR70","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0735-1097(92)90063-S","volume":"19","author":"MS Lauer","year":"1992","unstructured":"Lauer MS, Anderson KM, Levy D. Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol Elsevier. 1992;19:130\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"1092_CR71","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/archinte.162.12.1333","volume":"162","author":"A Hinderliter","year":"2002","unstructured":"Hinderliter A, Sherwood A, Gullette ECD, Babyak M, Waugh R, Georgiades A, et al. Reduction of left ventricular hypertrophy after exercise and weight loss in overweight patients with mild hypertension. Arch Intern Med. American Medical Association. 2002;162:1333.","journal-title":"Arch Intern Med"},{"key":"1092_CR72","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0895-7061(03)00894-X","volume":"16","author":"G Schillaci","year":"2003","unstructured":"Schillaci G, Pasqualini L, Vaudo G, Lupattelli G, Pirro M, Gemelli F, et al. Effect of body weight changes on 24-hour blood pressure and left ventricular mass in hypertension: a 4-year follow-up. Am J Hypertens Oxford Academic. 2003;16:634\u20139.","journal-title":"Am J Hypertens"},{"key":"1092_CR73","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.numecd.2018.10.010","volume":"29","author":"MT L\u00f8nnebakken","year":"2019","unstructured":"L\u00f8nnebakken MT, Mancusi C, Losi MA, Gerdts E, Izzo R, Manzi MV, et al. Weight loss facilitates reduction of left ventricular mass in obese hypertensive patients: the Campania Salute Network. Nutr Metab Cardiovasc Dis. 2019;29:185\u201390.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1092_CR74","doi-asserted-by":"crossref","unstructured":"Benotti PN, Wood GC, Carey DJ, Mehra VC, Mirshahi T, Lent MR, et al. Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure. J Am Heart Assoc. 2017;6(5):e005126.","DOI":"10.1161\/JAHA.116.005126"},{"key":"1092_CR75","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2019.14231","volume":"322","author":"A Aminian","year":"2019","unstructured":"Aminian A, Zajichek A, Arterburn DE, Wolski KE, Brethauer SA, Schauer PR, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019;322:1271.","journal-title":"JAMA."},{"key":"1092_CR76","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","volume":"307","author":"L Sj\u00f6str\u00f6m","year":"2012","unstructured":"Sj\u00f6str\u00f6m L, Peltonen M, Jacobson P, Sj\u00f6str\u00f6m CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56.","journal-title":"JAMA."},{"key":"1092_CR77","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/heartjnl-2012-301778","volume":"98","author":"AR Vest","year":"2012","unstructured":"Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98:1763\u201377.","journal-title":"Heart."},{"key":"1092_CR78","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ajh\/hpt215","volume":"27","author":"C Cuspidi","year":"2014","unstructured":"Cuspidi C, Rescaldani M, Tadic M, Sala C, Grassi G. Effects of bariatric surgery on cardiac structure and function: a systematic review and meta-analysis. Am J Hypertens. 2014;27:146\u201356.","journal-title":"Am J Hypertens"},{"key":"1092_CR79","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s11695-015-1866-5","volume":"26","author":"R Aggarwal","year":"2016","unstructured":"\u2022 Aggarwal R, Harling L, Efthimiou E, Darzi A, Athanasiou T, Ashrafian H. The effects of bariatric surgery on cardiac structure and function: a systematic review of cardiac imaging outcomes. Obes Surg. 2016;26:1030\u201340 This meta-analysis highlights the role of bariatric surgery in reducing LVH in populations with severe obesity, further underscoring the need for further prospective studies examining the effects on CVD with this invasive, durable weight-loss intervention.","journal-title":"Obes Surg"},{"key":"1092_CR80","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, D\u2019Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393\u2013401.","journal-title":"N Engl J Med"},{"key":"1092_CR81","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurheartj\/ehu441","volume":"36","author":"DE Kandzari","year":"2015","unstructured":"Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219\u201327.","journal-title":"Eur Heart J"},{"key":"1092_CR82","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/eurheartj\/ehu450","volume":"36","author":"F Mahfoud","year":"2015","unstructured":"Mahfoud F, L\u00fcscher TF. Renal denervation: Symply trapped by complexity? Eur Heart J. 2015;36:199\u2013202.","journal-title":"Eur Heart J"},{"key":"1092_CR83","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","volume":"390","author":"RR Townsend","year":"2017","unstructured":"Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160\u201370.","journal-title":"Lancet."},{"key":"1092_CR84","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"DE Kandzari","year":"2018","unstructured":"Kandzari DE, B\u00f6hm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346\u201355.","journal-title":"Lancet."},{"key":"1092_CR85","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s00392-016-0964-2","volume":"105","author":"D Lu","year":"2016","unstructured":"Lu D, Wang K, Liu Q, Wang S, Zhang Q, Shan Q. Reductions of left ventricular mass and atrial size following renal denervation: a meta-analysis. Clin Res Cardiol Springer. 2016;105:648\u201356.","journal-title":"Clin Res Cardiol"},{"key":"1092_CR86","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1097\/HJH.0000000000001798","volume":"36","author":"A Kordalis","year":"2018","unstructured":"Kordalis A, Tsiachris D, Pietri P, Tsioufis C, Stefanadis C. Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis. J Hypertens. 2018;36:1614\u201321.","journal-title":"J Hypertens"},{"key":"1092_CR87","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0895-7061(03)01018-5","volume":"16","author":"P Verdecchia","year":"2003","unstructured":"Verdecchia P, Angeli F, Borgioni C, Gattobigio R, De Simone G, Devereux RB, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16:895\u20139.","journal-title":"Am J Hypertens"},{"key":"1092_CR88","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/ajh.2010.80","volume":"23","author":"SD Pierdomenico","year":"2010","unstructured":"Pierdomenico SD, Cuccurullo F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens. 2010;23:876\u201381.","journal-title":"Am J Hypertens"},{"key":"1092_CR89","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.ijcard.2012.06.084","volume":"167","author":"P Costanzo","year":"2013","unstructured":"Costanzo P, Savarese G, Rosano G, Musella F, Casaretti L, Vassallo E, et al. Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients. Int J Cardiol. 2013;167:2757\u201364.","journal-title":"Int J Cardiol"},{"key":"1092_CR90","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jchf.2014.12.018","volume":"3","author":"SL Seliger","year":"2015","unstructured":"Seliger SL, de Lemos J, Neeland IJ, Christenson R, Gottdiener J, Drazner MH, et al. Older adults, \u201cmalignant\u201d left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (Cardiovascular Health Study). JACC Hear Fail. 2015;3:445\u201355.","journal-title":"JACC Hear Fail"},{"key":"1092_CR91","doi-asserted-by":"crossref","unstructured":"Peters MN, Seliger SL, Christenson RH, Hong-Zohlman SN, Daniels LB, Lima JAC, et al. \u201cMalignant\u201d left ventricular hypertrophy identifies subjects at high risk for progression to asymptomatic left ventricular dysfunction, heart failure, and death: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc. 2018;7(4):e006619.","DOI":"10.1161\/JAHA.117.006619"},{"key":"1092_CR92","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamacardio.2018.4300","volume":"4","author":"A Pandey","year":"2019","unstructured":"\u2022 Pandey A, Keshvani N, Ayers C, Correa A, Drazner MH, Lewis A, et al. Association of cardiac injury and malignant left ventricular hypertrophy with risk of heart failure in African Americans. JAMA Cardiol. 2019;4:51 This observational study in black participants demonstrated a five-fold higher risk of incident HF with the presence of malignant LVH. Black men in particular demonstrated a 15-fold higher risk of HF compared with a referent group of black men without LVH or subclinical myocardial injury.","journal-title":"JAMA Cardiol"},{"key":"1092_CR93","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/CIRCULATIONAHA.119.043628","volume":"141","author":"AA Lewis","year":"2020","unstructured":"\u2022 Lewis AA, Ayers CR, Selvin E, Neeland I, Ballantyne CM, Nambi V, et al. Racial differences in malignant left ventricular hypertrophy and incidence of heart failure: a multicohort study. Circulation. 2020;141:957\u201367 This multi-cohort study demonstrated a three-fold greater prevalence of malignant LVH in black participants compared with their white counterparts; the presence of malignant LVH was responsible for 33% and 11% of the excess hazard for HF among black men and women, respectively.","journal-title":"Circulation"},{"key":"1092_CR94","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijcard.2017.12.086","volume":"258","author":"E Gerdts","year":"2018","unstructured":"\u2022 Gerdts E, Izzo R, Mancusi C, Losi MA, Manzi MV, Canciello G, et al. Left ventricular hypertrophy offsets the sex difference in cardiovascular risk (the Campania Salute Network). Int J Cardiol. 2018;258:257\u201361 In this observational study, the presence of LVH in women offset any gender-related protective effects on CVD reported between women and men without LVH.","journal-title":"Int J Cardiol"},{"key":"1092_CR95","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/HYPERTENSIONAHA.107.107474","volume":"51","author":"E Gerdts","year":"2008","unstructured":"Gerdts E, Okin PM, de Simone G, Cramariuc D, Wachtell K, Boman K, et al. Gender differences in left ventricular structure and function during antihypertensive treatment. Hypertension. 2008;51:1109\u201314.","journal-title":"Hypertension."},{"key":"1092_CR96","doi-asserted-by":"crossref","first-page":"e000144","DOI":"10.1161\/JAHA.113.000144","volume":"2","author":"G De Simone","year":"2013","unstructured":"De Simone G, Devereux RB, Izzo R, Girfoglio D, Lee ET, Howard BV, et al. Lack of reduction of left ventricular mass in treated hypertension: the strong heart study. J Am Heart Assoc. 2013;2:e000144.","journal-title":"J Am Heart Assoc"},{"key":"1092_CR97","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/08037051.2013.858482","volume":"23","author":"C Mancusi","year":"2014","unstructured":"Mancusi C, Gerdts E, De Simone G, Abdelhai YM, Lonnebakken MT, Boman K, et al. Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). Blood Press. 2014;23:206\u201312.","journal-title":"Blood Press"},{"key":"1092_CR98","doi-asserted-by":"crossref","unstructured":"Piskorz D. Hypertensive mediated organ damage and hypertension management. How to assess beneficial effects of antihypertensive treatments? High Blood Press Cardiovasc Prev. 2020;27(10):1887\u2013920.","DOI":"10.1007\/s40292-020-00361-6"},{"key":"1092_CR99","doi-asserted-by":"crossref","unstructured":"Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, et al. 2016 European society of hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016.","DOI":"10.1097\/HJH.0000000000001039"},{"key":"1092_CR100","doi-asserted-by":"crossref","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904.","DOI":"10.1542\/peds.2017-3035"},{"key":"1092_CR101","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40292-019-00345-1","volume":"26","author":"D Marcon","year":"2019","unstructured":"Marcon D, Tagetti A, Fava C. Subclinical organ damage in children and adolescents with hypertension: current guidelines and beyond. High Blood Press Cardiovasc Prev. 2019;26:361\u201373.","journal-title":"High Blood Press Cardiovasc Prev"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-020-01092-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-020-01092-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-020-01092-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,5]],"date-time":"2021-09-05T00:02:02Z","timestamp":1630800122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-020-01092-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,5]]},"references-count":101,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1092"],"URL":"https:\/\/doi.org\/10.1007\/s11906-020-01092-8","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,5]]},"assertion":[{"value":"5 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"85"}}